Semin Thromb Hemost 2018; 44(02): 081-088
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
2017 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards
Emmanuel J. Favaloro
1
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead, Australia
› Author Affiliations
References
1
Favaloro EJ.
Editorial. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008; 34: 693-696
2
Favaloro EJ.
A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707
3
Favaloro EJ.
Editorial. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009; 35: 1-2
4
Favaloro EJ.
Editorial. Winners of the inaugural Eberhard F. Mammen award for most popular article. Semin Thromb Hemost 2009; 35: 587-590
5
Favaloro EJ.
Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010; 36: 469-470
6
Favaloro EJ.
Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008-2009. Semin Thromb Hemost 2010; 36 (07) 685-692
7
Favaloro EJ.
2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011; 37 (05) 431-439
8
Favaloro EJ.
2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012; 38: 425-432
9
Favaloro EJ.
Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013; 39: 567-574
10
Favaloro EJ.
2014 Eberhard F. Mammen award announcements: part I-most popular articles. Semin Thromb Hemost 2014; 40 (04) 407-412
11
Favaloro EJ.
2014 Eberhard F. Mammen award announcements: part II–Young Investigator Awards. Semin Thromb Hemost 2014; 40 (07) 718-723
12
Favaloro EJ.
2015 Eberhard F. Mammen award announcements: part I--most popular articles. Semin Thromb Hemost 2015; 41 (07) 673-679
13
Favaloro EJ.
2015 Eberhard F. Mammen award announcements: part II–Young Investigator Awards. Semin Thromb Hemost 2015; 41 (08) 809-815
14
Favaloro EJ.
2016 Eberhard F. Mammen award announcements: part I–most popular articles. Semin Thromb Hemost 2016; 42 (04) 325-330
15
Favaloro EJ.
2016 Eberhard F. Mammen award announcements: part II–Young Investigator Awards. Semin Thromb Hemost 2017; 43 (03) 235-241
16
Favaloro EJ.
2017 Eberhard F. Mammen award announcements: part I–most popular articles. Semin Thromb Hemost 2017; 43 (04) 357-363
17
Lijfering WM,
Flinterman LE,
Vandenbroucke JP,
Rosendaal FR,
Cannegieter SC.
Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011; 37 (08) 885-896
18
Pels SG.
Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost 2011; 37 (06) 621-630
19
Cuker A.
Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost 2012; 38 (01) 31-37
20
Jayandharan GR,
Srivastava A,
Srivastava A.
Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost 2012; 38 (01) 64-78
21
Szántó T,
Joutsi-Korhonen L,
Deckmyn H,
Lassila R.
New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38 (01) 55-63
22
Salmela B,
Joutsi-Korhonen L,
Armstrong E,
Lassila R.
Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (01) 23-30
23
Aatonen M,
Grönholm M,
Siljander PR.
Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012; 38 (01) 102-113
24
Lacroix R,
Dignat-George F.
Microparticles: new protagonists in pericellular and intravascular proteolysis. Semin Thromb Hemost 2013; 39 (01) 33-39
25
McEwen BJ,
Morel-Kopp MC,
Chen W,
Tofler GH,
Ward CM.
Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost 2013; 39 (01) 25-32
26
Bernard TJ,
Armstrong-Wells J,
Goldenberg NA.
The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. Semin Thromb Hemost 2013; 39 (01) 10-14
27
Italiano Jr JE.
Unraveling mechanisms that control platelet production. Semin Thromb Hemost 2013; 39 (01) 15-24
28
Du VX,
Huskens D,
Maas C,
Al Dieri R,
de Groot PG,
de Laat B.
New insights into the role of erythrocytes in thrombus formation. Semin Thromb Hemost 2014; 40 (01) 72-80
29
Yee A,
Kretz CA.
Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (01) 17-27
30
O'Brien SH.
Contraception-related venous thromboembolism in adolescents. Semin Thromb Hemost 2014; 40 (01) 66-71
31
Flood VH.
Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost 2014; 40 (01) 41-48
32
Tange JI,
Grill D,
Koch CD.
, et al. Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost 2014; 40 (01) 115-120
33
Chapman K,
Yuen S.
Therapy for thrombotic thrombocytopenia purpura: past, present, and future. Semin Thromb Hemost 2014; 40 (01) 34-40
34
Tiede A,
Werwitzke S,
Scharf RE.
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 2014; 40 (07) 803-811
35
Lim W.
Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost 2014; 40 (07) 741-746
36
Fernandes S,
Carvalho M,
Lopes M,
Araújo F.
Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost 2014; 40 (07) 785-789
37
Mancuso ME,
Fasulo MR.
Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost 2016; 42 (01) 30-35
38
Tersteeg C,
Fijnheer R,
Pasterkamp G.
, et al. Keeping von Willebrand factor under control: alternatives for ADAMTS13. Semin Thromb Hemost 2016; 42 (01) 9-17
39
Kumar R,
Dunn A,
Carcao M.
Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. Semin Thromb Hemost 2016; 42 (01) 18-29
40
Sokol J,
Skerenova M,
Jedinakova Z.
, et al. Progress in the understanding of sticky platelet syndrome. Semin Thromb Hemost 2017; 43 (01) 8-13
41
Jovanovic L,
Antonijevic N,
Novakovic T.
, et al. Practical aspects of monitoring of antiplatelet therapy. Semin Thromb Hemost 2017; 43 (01) 14-23
42
Stanciakova L,
Dobrotova M,
Jedinakova Z.
, et al. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. Semin Thromb Hemost 2016; 42 (06) 612-621
43
Biss TT.
Venous thromboembolism in children: is it preventable?. Semin Thromb Hemost 2016; 42 (06) 603-611
44
Jiménez-Alcázar M,
Kim N,
Fuchs TA.
Circulating extracellular DNA – cause or consequence of thrombosis?. Semin Thromb Hemost 2017; 43 (06) 553-561
45
Silvis SM,
Middeldorp S,
Zuurbier SM,
Cannegieter SC,
Coutinho JM.
Risk factors for cerebral venous thrombosis. Semin Thromb Hemost 2016; 42 (06) 622-631
46
Selvam S,
James P.
Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. Semin Thromb Hemost 2017; 43 (06) 572-580
47
Muczynski V,
Christophe OD,
Denis CV,
Lenting PJ.
Emerging therapeutic strategies in the treatment of hemophilia A. Semin Thromb Hemost 2017; 43 (06) 581-590
48
Schreiber K,
Breen K,
Cohen H.
, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43 (06) 562-571
49
Tay J,
Tiao J,
Hughes Q,
Jorritsma J,
Gilmore G,
Baker R.
Circulating microRNA as thrombosis sentinels: caveats and considerations. Semin Thromb Hemost 2018;
50
Klil-Drori AJ,
Tagalakis V.
Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018;
51
Chapman K,
Seldon M,
Richards R.
Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38 (01) 47-54
